vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and AVITA Medical, Inc. (RCEL), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $17.6M, roughly 39.7× AVITA Medical, Inc.). AVITA Medical, Inc. runs the higher net margin — -104.7% vs -66.0%, a 38.8% gap on every dollar of revenue. On growth, QuidelOrtho Corp posted the faster year-over-year revenue change (-3.7% vs -4.3%). AVITA Medical, Inc. produced more free cash flow last quarter ($-6.1M vs $-94.7M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs -2.9%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...
QDEL vs RCEL — Head-to-Head
Income Statement — Q3 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $699.9M | $17.6M |
| Net Profit | $-733.0M | $-11.6M |
| Gross Margin | — | 81.2% |
| Operating Margin | -100.7% | -59.1% |
| Net Margin | -104.7% | -66.0% |
| Revenue YoY | -3.7% | -4.3% |
| Net Profit YoY | -3583.4% | -0.3% |
| EPS (diluted) | $-10.78 | $-0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | — | $17.6M | ||
| Q3 25 | $699.9M | $17.1M | ||
| Q2 25 | $613.9M | $18.4M | ||
| Q1 25 | $692.8M | $18.5M | ||
| Q4 24 | $707.8M | $18.4M | ||
| Q3 24 | $727.1M | $19.5M | ||
| Q2 24 | $637.0M | $15.2M | ||
| Q1 24 | $711.0M | $11.1M |
| Q4 25 | — | $-11.6M | ||
| Q3 25 | $-733.0M | $-13.2M | ||
| Q2 25 | $-255.4M | $-9.9M | ||
| Q1 25 | $-12.7M | $-13.9M | ||
| Q4 24 | $-178.4M | $-11.6M | ||
| Q3 24 | $-19.9M | $-16.2M | ||
| Q2 24 | $-147.7M | $-15.4M | ||
| Q1 24 | $-1.7B | $-18.7M |
| Q4 25 | — | 81.2% | ||
| Q3 25 | — | 81.3% | ||
| Q2 25 | — | 81.2% | ||
| Q1 25 | — | 84.7% | ||
| Q4 24 | — | 87.6% | ||
| Q3 24 | — | 83.7% | ||
| Q2 24 | — | 86.1% | ||
| Q1 24 | — | 86.4% |
| Q4 25 | — | -59.1% | ||
| Q3 25 | -100.7% | -53.6% | ||
| Q2 25 | -29.4% | -60.5% | ||
| Q1 25 | 4.7% | -63.9% | ||
| Q4 24 | -14.2% | -54.1% | ||
| Q3 24 | 2.1% | -70.6% | ||
| Q2 24 | -18.4% | -102.8% | ||
| Q1 24 | -247.3% | -155.0% |
| Q4 25 | — | -66.0% | ||
| Q3 25 | -104.7% | -77.3% | ||
| Q2 25 | -41.6% | -53.9% | ||
| Q1 25 | -1.8% | -74.9% | ||
| Q4 24 | -25.2% | -63.0% | ||
| Q3 24 | -2.7% | -82.9% | ||
| Q2 24 | -23.2% | -101.3% | ||
| Q1 24 | -239.9% | -168.0% |
| Q4 25 | — | $-0.37 | ||
| Q3 25 | $-10.78 | $-0.46 | ||
| Q2 25 | $-3.77 | $-0.38 | ||
| Q1 25 | $-0.19 | $-0.53 | ||
| Q4 24 | $-2.54 | $-0.44 | ||
| Q3 24 | $-0.30 | $-0.62 | ||
| Q2 24 | $-2.20 | $-0.60 | ||
| Q1 24 | $-25.50 | $-0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.1M | $18.2M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $2.0B | $-16.6M |
| Total Assets | $5.7B | $56.4M |
| Debt / EquityLower = less leverage | 1.23× | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | — | $18.2M | ||
| Q3 25 | $98.1M | $23.3M | ||
| Q2 25 | $151.7M | $15.7M | ||
| Q1 25 | $127.1M | $25.8M | ||
| Q4 24 | $98.3M | $35.9M | ||
| Q3 24 | $143.7M | $44.4M | ||
| Q2 24 | $107.0M | $54.1M | ||
| Q1 24 | $78.5M | $68.2M |
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | — | $-16.6M | ||
| Q3 25 | $2.0B | $-6.7M | ||
| Q2 25 | $2.8B | $-12.9M | ||
| Q1 25 | $3.0B | $-4.6M | ||
| Q4 24 | $3.0B | $4.5M | ||
| Q3 24 | $3.2B | $12.2M | ||
| Q2 24 | $3.2B | $23.9M | ||
| Q1 24 | $3.3B | $32.6M |
| Q4 25 | — | $56.4M | ||
| Q3 25 | $5.7B | $63.7M | ||
| Q2 25 | $6.4B | $58.1M | ||
| Q1 25 | $6.5B | $69.6M | ||
| Q4 24 | $6.4B | $79.7M | ||
| Q3 24 | $6.8B | $81.1M | ||
| Q2 24 | $6.7B | $87.8M | ||
| Q1 24 | $6.7B | $97.4M |
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-45.5M | $-5.4M |
| Free Cash FlowOCF − Capex | $-94.7M | $-6.1M |
| FCF MarginFCF / Revenue | -13.5% | -34.7% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 7.0% | 3.8% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-153.1M | $-33.5M |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | — | $-5.4M | ||
| Q3 25 | $-45.5M | $-5.2M | ||
| Q2 25 | $-46.8M | $-10.2M | ||
| Q1 25 | $65.6M | $-10.3M | ||
| Q4 24 | $63.7M | $-8.1M | ||
| Q3 24 | $117.9M | $-7.2M | ||
| Q2 24 | $-97.9M | $-12.8M | ||
| Q1 24 | $-700.0K | $-20.9M |
| Q4 25 | — | $-6.1M | ||
| Q3 25 | $-94.7M | $-6.2M | ||
| Q2 25 | $-84.3M | $-10.8M | ||
| Q1 25 | $9.4M | $-10.5M | ||
| Q4 24 | $16.5M | $-9.7M | ||
| Q3 24 | $71.4M | $-11.0M | ||
| Q2 24 | $-133.2M | $-15.4M | ||
| Q1 24 | $-66.8M | $-22.0M |
| Q4 25 | — | -34.7% | ||
| Q3 25 | -13.5% | -36.1% | ||
| Q2 25 | -13.7% | -58.4% | ||
| Q1 25 | 1.4% | -56.9% | ||
| Q4 24 | 2.3% | -52.7% | ||
| Q3 24 | 9.8% | -56.1% | ||
| Q2 24 | -20.9% | -101.6% | ||
| Q1 24 | -9.4% | -198.2% |
| Q4 25 | — | 3.8% | ||
| Q3 25 | 7.0% | 5.5% | ||
| Q2 25 | 6.1% | 2.8% | ||
| Q1 25 | 8.1% | 1.2% | ||
| Q4 24 | 6.7% | 8.8% | ||
| Q3 24 | 6.4% | 19.2% | ||
| Q2 24 | 5.5% | 17.5% | ||
| Q1 24 | 9.3% | 10.3% |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
RCEL
Segment breakdown not available.
